Connect with us

Work

How John 5 Landed His Guitarist Gig With David Lee Roth

Published

on

Talent will only get you so far, and if there’s a case to be made for initiative taking you that extra step, John 5 could certainly be an example of that. Though the guitarist’s career has included a number of high profile stints, one of the earliest came with David Lee Roth and he detailed how a little initiative put him on the path to landing that gig during an interview with The Sessions’ Artist Series (as seen below).

John 5 revealed (as transcribed by Blabbermouth), “I was reading [Roth’s 1998 autobiography ‘Crazy From the Heat’]. I was at my friend’s house. And there was a number in the back of the book where you could get ahold of the management company. And I thought to myself, ‘Hmm, I think I’m going to reach out and call this number and see what’s going on.’ ‘Cause I knew Dave wasn’t doing much at the time, and I loved Van Halen, and I loved Dave Lee Roth.”

“I said, ‘Are you guys accepting any [music] right now or anything like that?’ And they said, ‘Well, not really. But you can send a CD, and we’ll see what we’ve got.’ And I was, like, ‘Oh my God!’ Just that little bit, I was shocked. I was, like, ‘This is insane.’ So I go there. I record with [producer] Bob Marlette. And I do my best Van Halen — I do ‘Slam Dunk’ and I do all these songs. Of course, no vocals — just my best Van Halen impersonation. And I sent it to them, and they said, ‘We like it. Can you send three more?'”

John 5 says he thought at the time, “This is the most crazy thing ever,” but he went ahead and sent what was requested only to be asked for three more recordings. When he admitted he didn’t have the money to go back in and record more, he was told by Roth’s management that the singer wanted to meet him.

“Listen, David Lee Roth is not around; he’s not hanging out. It’s very hard to meet David Lee Roth. And I go to his house. And this is the house where they filmed ‘Pretty Woman,’ they did all the photo shoots for the early Van Halen, they rehearsed in this basement. And this is the house. And there’s Dave in his overalls,” recalls the guitarist. “And he’s, like, ‘John, great to see ya. We’re gonna make a record. I really like what you’re doing.’ And I was, like, ‘Oh my God.’ I couldn’t believe it.”

John 5 says he later after he was more comfortable, he had Roth sign a copy of his book. “So, you just have to go after things and do things and make it work,” says the guitarist.

John 5 appeared on the 1998 DLR Band album and remained a part of Roth’s band until 2003. These days the guitarist is a member of Rob Zombie‘s band in addition to releasing his own solo material.

John 5 Speaks With The Sessions’ Artist Series

66 Best Hard Rock + Metal Guitarists of All-Time



Source link

Work

Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig – Endpoints News

Published

on

By

Fac­ing hun­dreds of law­suits over its role in fu­el­ing the US opi­oid epi­dem­ic, Pur­due Phar­ma is in the midst of full-scale tear­down — but that doesn’t mean its for­mer lead­ers aren’t mak­ing off well. Com­ing off a stint dri­ving RNAi ther­a­py in­clisir­an to a buy­out, for­mer Pur­due CEO Mark Tim­ney has found a new home at the helm of a small biotech.

On Mon­day, At­tralus Ther­a­peu­tics an­nounced Tim­ney’s hire as CEO amid a flur­ry of ad­di­tions to the biotech’s brain trust.

As the CEO dri­ving Pur­due dur­ing some of the worst years of the opi­oid epi­dem­ic, Tim­ney has been named in dozens of law­suits against the Oxy­Con­tin mak­er. He joined The Med­i­cines Com­pa­ny as its CEO in De­cem­ber 2018 af­ter four years as the pres­i­dent and CEO of Pur­due. In 2019, he snagged an $84 mil­lion wind­fall when that com­pa­ny was bought by No­var­tis for $9.7 bil­lion.

In a state­ment, Tim­ney said that he was ex­cit­ed about At­tralus’ pan-amy­loid re­moval ther­a­pies for pa­tients with sys­temic amy­loi­do­sis, cit­ing the ex­ten­sive un­met needs sur­round­ing the dis­ease. Nei­ther he nor At­tralus men­tioned any­thing about his time at Pur­due in the press re­lease, ex­cept for a brief men­tion that he held a se­nior role there.

The state­ment tout­ed his years of ex­pe­ri­ence in the in­dus­try and his lead­er­ship of The Med­i­cines Com­pa­ny through late-stage clin­i­cal de­vel­op­ment and max­i­mized the po­ten­tial for in­clisir­an, a siR­NA cho­les­terol low­er­ing ther­a­py.

“These ac­tions in­creased share­hold­er re­turn more than three-fold with­in one year and cul­mi­nat­ed in the com­pa­ny’s ac­qui­si­tion by No­var­tis,” the state­ment said.

Dur­ing his time at Pur­due, Tim­ney al­leged­ly di­rect­ed sales reps to pro­mote Oxy­Con­tin’s “abuse-de­ter­rent prop­er­ties,” even though he didn’t dis­close that those prop­er­ties didn’t help with over­con­sump­tion of the drug, the AP said. Tim­ney and his pre­de­ces­sor John Stew­art were ac­cused of par­tic­i­pat­ing di­rect­ly in de­cep­tive prac­tices and al­leged­ly gave pre­sen­ta­tions that ac­knowl­edged that the an­ti-abuse tech­nol­o­gy was un­like­ly to work. He is named as a de­fen­dant in more than 30 law­suits against Pur­due from over 1,000 cities and states, in­clud­ing Col­orado, Mass­a­chu­setts and Con­necti­cut.

Richard Gaster

So far, Pur­due has reached a num­ber of set­tle­ments, in­clud­ing one in March 2019 for $270 mil­lion with the state of Ok­la­homa. The com­pa­ny is cur­rent­ly mired in a court-su­per­vised re­struc­tur­ing.

Nei­ther At­tralus nor Tim­ney re­spond­ed by press time.

“We are pleased to wel­come Mark Tim­ney as CEO of At­tralus, as he brings a track record for de­liv­er­ing val­ue for pa­tients, health care sys­tems and in­vestors,” At­tralus board mem­ber Richard Gaster said in the re­lease.

Rahul Kakkar, a biotech en­tre­pre­neur and the CEO of Pan­dion Ther­a­peu­tics be­fore it was ac­quired by Mer­ck, was named as an At­tralus board mem­ber Mon­day. Gre­go­ry Bell comes to the com­pa­ny to fill the role of CMO from KAI Phar­ma­ceu­ti­cals. Glen Fire­stone was named the CBO, Kr­ish­na Gor­ti was named the head of cor­po­rate de­vel­op­ment and Michael Klein was named the head of chem­istry, man­u­fac­tur­ing and con­trols.

At­tralus’ pan-amy­loid re­moval ther­a­peu­tic is de­signed to di­rect­ly bind and re­move tox­ic amy­loid in or­gans and tis­sues, and has the po­ten­tial to treat pa­tients with all types and stages of amy­loi­do­sis.

Source link

Continue Reading

Work

Christopher Robbins Joins Streetsblog for Mayoral Campaign Gig – Streetsblog New York City

Published

on

By

Gothamist’s foolishness is Streetsblog’s gain.

Starting this week, and continuing through the June 22 primary elections, former Gothamist editor and reporter Christopher Robbins will be reporting for us on the mayoral race.

Robbins dove right in yesterday, covering the street fight in Times Square between Andrew Yang and Eric Adams on policing.

The opportunity presented itself in late April when Gothamist parted company with the veteran reporter and union leader for no stated reason. Streetsblog Publisher Mark Gorton moved quickly.

“Streetsblog has done a great job highlighting the struggles of the city to move from car-dominated to people-oriented streets, but as the election draws near, our reporters have been tasked with staying on top of both the daily fight for safe streets and also dynamics of the election races,” Gorton said. “Adding Chris Robbins to our team will help us expand the breadth of our coverage over the next six weeks. We look forward to some great engagement with the candidates.”

For Robbins’s part, look, it’s a temporary gig, but he’s going into it full throttle:

“New Yorkers are still busy dealing with the anguish and trauma of a devastating global pandemic and figuring out how to move forward towards an exciting if uncertain future. Now we have to pick a mayor, too? My goal is to help us all figure out what these candidates stand for and how they’ll address the biggest challenges this city faces,” Robbins said. “I want to connect existential questions (How will we prevent climate annihilation? How can a mayor stem economic inequality and racial injustice?) with quotidian concerns (Will street parking be forever free? Who will make the buses faster fastest?).

“I will do my best to ask annoying questions, write thoughtful analysis, and report on the current state of the race without being breathless or boring,” Robbins added.

So if you’re a reader with a hot tip — or a candidate who wants to spin your way off Robbins’s hook — email him by clicking here. And follow him on Twitter at @christrobbins.



Source link

Continue Reading

Work

Paris Teenager’s New Gig: Would-Be Queen of Italy. A Nation Shrugs. – The New York Times

Published

on

By

Continue Reading

Trending

Copyright © 2019 Gigger.news.